EBV-positive diffuse large B-cell lymphoma in a patient with primary Sjögren’s syndrome and membranous glomerulonephritis by Chang Seong Kim et al.
Kim et al. BMC Nephrology 2012, 13:149
http://www.biomedcentral.com/1471-2369/13/149CASE REPORT Open AccessEBV-positive diffuse large B-cell lymphoma in a
patient with primary Sjögren’s syndrome and
membranous glomerulonephritis
Chang Seong Kim1, Yoo Duk Choi2, Joon Seok Choi1, Eun Hui Bae1, Seong Kwon Ma1 and Soo Wan Kim1*Abstract
Background: Sjögren’s syndrome is a systemic autoimmune disease in which lymphatic cells destroy the salivary
and lacrimal glands. Glomerulonephritis is thought to be a rare occurrence in primary Sjögren’s syndrome.
Furthermore, concurrent glomerular involvement and lymphoma in patients with Sjögren’s syndrome has seldom
been reported.
Case presentation: A 52-year-old woman with primary Sjögren’s syndrome developed membranous
glomerulonephritis and Epstein-Barr virus-positive diffuse large B-cell lymphoma (DLBCL). She was diagnosed with
Sjögren’s syndrome based on the dry eyes, dry mouth, positive anti-nuclear antibody test, anti-Ro (SS-A) antibody,
salivary gland biopsy, and salivary scintigraphy. Moreover, renal biopsy confirmed the diagnosis of membranous
glomerulonephritis. Three months later, her small bowel was perforated with pneumoperitoneum, and the biopsy
revealed Epstein-Barr virus-positive DLBCL.
Conclusions: We observed the first case of primary Sjögren’s syndrome associated with Epstein-Barr Virus-positive
DLBCL and membranous glomerulonephritis. Because of the possibility of malignancy-associated membranous
glomerulonephritis in patients with primary Sjögren’s syndrome, we should be careful and examine such patients
for hidden malignancy.
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Sjögren’s syndrome is an autoimmune disease character-
ized by lymphocytic infiltration of salivary and lacrimal
glands, typically presenting with keratoconjunctivitis and
xerostomia [1]. Extraglandular manifestations of Sjög-
ren’s syndrome occur in up to a third of patients [2]. Pa-
tients with Sjögren’s syndrome can have accompanying
interstitial lung disease [3], cutaneous vasculitis [4], per-
ipheral neuropathy [5], hematologic complications [6],
and renal involvement. Tubulointerstitial nephritis is the
most common renal manifestation of primary Sjögren’s
syndrome; whereas, glomerulonephritis is rare in com-
parison [7]. On the other hand, the most feared compli-
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reproduction in any medium, provided the ormalignancy. The risk of malignant non-Hodgkin’s lymph-
oma (NHL) is increased in primary Sjögren’s syndrome
[6]. Moreover, Epstein-Barr virus (EBV)-positive diffuse
large B-cell lymphoma (DLBCL) is rarer and is associated
with poorer overall survival than EBV-negative DLBCL.
In addition, intestinal involvement and perforation is
very rare. Here, we report the case of a 52-year-old
woman diagnosed with primary Sjögren’s syndrome as-
sociated with EBV-positive DLBCL and membranous
glomerulonephritis.
Case presentation
A 52-year-old woman was admitted to hospital for eval-
uation of intermittent abdominal tenderness, dry eye,
and dry mouth. The dry eye and dry mouth had been
present for several years; however, she had not sought
medical treatment for these symptoms. She had a history
of dilated cardiomyopathy and glaucoma of the left eye.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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inhibitors, and anthocyanosides for glaucoma. In the
physical examination, her lower extremities were in an
edematous state. Her body temperature was 36.5°C and
blood pressure was normal. The results of the laboratory
studies were as follows: white blood cell count, 8,600/
mm3 (neutrophil 73.4%); sodium, 141 mEq/L; chloride,
108 mEq/L; blood urea nitrogen, 15.7 mg/dL; and cre-
atinine, 0.6 mg/dL. The levels of total serum protein,
serum albumin, and total cholesterol were 5.5 g/dL, 1.5
g/dL, and 257 mg/dL, respectively. Urinalysis was re-
markable for proteinuria (6.3 g/day), 30–49 red blood
cells per high-power field, but no other casts. Serologic
investigation revealed the presence of anti-nuclear anti-
body (ANA; 1:80, homogeneous plus speckled pattern),
rheumatoid factor (390 IU/mL), and was positive for
autoantibody to the Ro (SS-A) antigen (>200 U/mL).
However, serology was negative for antibodies against
double-stranded DNA, La (SS-B), Sm, ribonucleoproteins,
antineutrophil cytoplasmic antibodies, lupus anticoagu-
lant, IgG/IgM anti-cardiolipin, and IgG β2-glycoprotein-1.
The C3 levels had decreased to 38 mg/dL (normal, 90–180
mg/dL), whereas C4 and total hemolytic complement 50
levels were within normal ranges at 16 mg/dL and 33.1
U/mL, respectively (normal ranges, 10–40 and 23–46, re-
spectively). Tests for hepatitis B surface antigen, hepatitis
C antibodies, cryoglobulins, and human immunodeficien-
cy virus antibodies were negative.
Minor salivary gland biopsy was performed, showing
diffuse lymphocytic infiltrations with a focus score of 3
[8]. Moreover, we performed salivary scintigraphy that
showed non-visualization in both salivary glands, con-
sistent with the class 4 Schall grading system [9]. There-
fore, she was diagnosed with Sjögren’s syndrome based
on the dry eyes, dry mouth, positive ANA, anti-Ro (SS-A)
antibody, salivary gland biopsy, and salivary scintigraphy,
which fulfilled the 2002 American-European consensus
classification criteria [10].
She underwent a percutaneous renal biopsy due to
nephrotic syndrome. Glomerular basement membraneFigure 1 Percutaneous renal biopsy. (A) On light microscopy, glomeruli
normocellularity (Magnification: x400). (B) On electron microscopy, diffuse s
(Magnification: x2500).thickening and mesangial matrix widening were ob-
served by light microscopy (Figure 1A). In addition, mild
tubular atrophy and moderate interstitial fibrosis was
noted. Weakly positive staining for IgG, IgA, IgM, and
C3 on the outer surface of capillary walls was revealed
by immunofluorescent staining. Diffuse subepithelial
electron-dense deposit was observed by electron micros-
copy (Figure 1B). The histopathological findings were
consistent with membranous glomerulonephritis [11].
Abdominal computed tomography (CT) and colonos-
copy were performed due to intermittent abdominal ten-
derness; however, we did not observe any malignancy or
bowel perforation at admission except for enteritis and
multiple small lymphadenopathies in the mesentery. She
had sudden onset of severe abdominal pain 3 months
later, and abdominal CT was performed again. Newly de-
veloped pneumoperitoneum with peritonitis accompan-
iedby small bowelperforationwasobserved.Anemergency
operation and small bowel biopsy were performed. The
specimen was 9.5 cm in axial length and had a necrotic
and ulcerous (4.5 × 5 cm) lesion. On immunohistochem-
ical examination, we found expression of CD20, CD79a,
and BCL-2, but not of CD3, CD10, and BCL-6. The pro-
liferation fraction as determined by Ki-67 was 50%–60%.
The majority of tumor cells were positive for EBV by in
situ hybridization. Biopsy revealed EBV-positive DLBCL
(Ann Harbor classification stage III), as demonstrated in
Figure 2. The patient declined treatment with chemother-
apy because of poor performance status, low compliance,
and poverty. However, she had been receiving intermittent
low-dose oral corticosteroid and hydroxychloroquine to
treat her primary Sjögren’s syndrome since the diagnosis.
There was improvement in proteinuria (1.79 g/day) and
sicca symptoms after 1 year of follow-up. One year of
follow-up positron emission tomography-CTscan showed
a stable disease state for the malignant lymphoma.
Conclusions
Lymphoma is more common in patients with auto-
immune disease, especially those with primary Sjögren’sshow a diffuse thickening of basement membrane with
ubepithelial electron dense deposits are easily identified.
Figure 2 Small bowel biopsy. (A) The tumor cells have immunoreactivity for CD20. (Magnification: x100). (B) The tumor cells have a positive
reaction for EBV in situ hybridization. (Magnification: x100).
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Sjögren’s syndrome was found to be 16–44 times higher
than in the general population in 2 large case series
studies [12,13]. Patients with primary Sjögren’s syndrome
have risk factors for progression to lymphoma, such as
persistent enlarged parotid glands, splenomegaly, lympa-
denopathy, palpable purpura, leg ulcers, peripheral nerve
involvement, anemia, neutropenia, low-grade fever, low
levels of C3 and C4, and mixed cryoglobulinemia [13]. In
this case, risk factors for malignant lymphoma included
low levels of C3, anemia, and multiple small lymphade-
nopathies detected by abdominal CT.
EBV-positive DLBCL is characterized by EBV-positive
clonal B cell lymphoproliferation that occurs in patients
aged over 50 years without any immunodeficiency or
prior lymphoma. It is a recently defined subgroup of
DLBCL in the 2008 World Health Organization classifi-
cation of lymphoid neoplasm [14]. The pathogenetic role
of the EBV in NHL is circumstantial; however, EBV is
able to drive cellular proliferation as a potential carcino-
gen [15]. In this case, we speculated that this virus
assisted in the progression of the malignant lymphoma.
Patients with age-related EBV-positive DLBCL are older,
have more aggressive clinical features, are rarer (9%)
[16], and have poorer overall survival, as compared with
EBV-negative DLBCL patients. Lymphoma complicated
with Sjögren’s syndrome is usually localized in extrano-
dal areas such as salivary glands, the gastrointestinal
tract, the thyroid gland, lung, kidney, or orbit [17]; how-
ever, common sites of extranodal involvement in EBV-
positive DLBCL are skin, lung, pleural effusion, stomach,
and tonsil [18]. Concurrent primary small-bowel involve-
ment and perforation is a very rare clinical manifestation
in patients with EBV-positive DLBCL [19], especially in
those with accompanying Sjögren’s syndrome.
Interestingly in our case, it is possible that secondary
membranous glomerulonephritis was related to primary
Sjögren’s syndrome or malignant lymphoma. Clinically
significant renal disease is rare in primary Sjögren’s syn-
drome, but latent involvement is relatively common.
Renal abnormalities have been reported at varying rates,from 3% to 67%, in patients with primary Sjögren’s syn-
drome, according to different studies [20-24]. Neverthe-
less, Kaufman et al. [2] analyzed 180 case reports of
renal involvement in primary Sjögren’s syndrome in a re-
view of the literature; in 89 cases, patients underwent
renal biopsies that revealed interstitial nephritis in 49
cases (55%), glomerulonephritis in 33 cases (37%), and
both interstitial nephritis and glomerulonephritis in 7
cases (8%). However, renal biopsies been performed in
only half of the reported cases; therefore, the true preva-
lence of membranous glomerulonephritis remains un-
known. There have been only 3 previous cases reported
of membranous glomerulonephritis and primary Sjög-
ren’s syndrome, to our knowledge [7,25]. From a differ-
ent point of view, patients with NHL manifest a great
variety of glomerular lesions, and several case reports on
glomerulonephritis associated with NHL have been pub-
lished [26-30]. In addition, even if membranoproliferative
glomerulonephritis was more common, membranous
glomerulonephritis has been reported in 5 of 47 cases
(approximately 10%) among glomerulopathies associated
with NHL, in a study by Ronco et al. [31]. Furthermore,
the onset of proteinuria occurs with the development of
lymphoma, or may slightly precede the clinical detection
of lymphoma by several months. There have been several
case reports where nephritic syndrome was detected
prior to the diagnosis of NHL [32-36]. In our case, the
patient presented with nephritic syndrome more than
3 months prior to the diagnosis of NHL. In this context,
we can tentatively propose the possibility that the sec-
ondary membranous glomerulonephritis was related to
DLBCL in this case.
Serological abnormalities including those of rheuma-
toid factor, cryoglobulins, ANA, anti-Ro, and anti-La are
common in secondary glomerulonephritis with Sjögren’s
syndrome; however, serum complement levels are gener-
ally normal unless the patient has associated systemic
lupus erythematosus. Goules et al. reported the immu-
nological profile of 10 patients with glomerulonephritis
in Sjögren’s syndrome; 2 patients demonstrated low
levels of C3, 5 patients had decreased C4 serum levels,
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serum levels. These findings are consistent with those of
our case, in which the patient had low C3 and normal
C4 levels. The underlying mechanisms are still not com-
pletely understood, however, there are varying forms of
complement abnormalities in renal involvement accom-
panying Sjögern’s syndrome. Therefore, further study is
needed to better understand complement abnormalities.
Although only a few case reports have described treat-
ment with corticosteroid alone or in combination with
cyclophosphamide in primary Sjögren’s syndrome with
renal disease, such treatment has generally led to good
clinical outcomes [2]. In 1 case report [36], Sjögren’s
syndrome complicated with membranous glomerulo-
nephritis resulting from malignant lymphoma resolved
after treatment with CHOP (cyclophosphamide, doxo-
rubicin, vincristine, and predinisolone) and radiation.
Nevertheless, our patient could not be treated with im-
munosuppressive therapy or chemotherapy because of
her poor general condition. We anticipate that an ad-
equate treatment would be helpful for improvement of
the disease.
In conclusion, to the best of our knowledge, we report
the first case of primary Sjögren’s syndrome associated
with EBV-positive DLBCL and membranous glomerulo-
nephritis. If patients with primary Sjögren’s syndrome
show concurrent membranous glomerulonephritis, they
should be carefully examined for hidden malignancy, in-
cluding EBV-positive DLBCL, because of the possibility
of malignancy-associated membranous glomerulonephritis.
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